Boehringer Ingelheim 2015 sales up over 11% in euro terms

In 2015, family-owned German pharma major Boehringer Ingelheim generated net sales of 14.8 billion euros, representing an increase of 4.1% in currency-adjusted terms (+11.1 % in euro terms).

Excluding the generics business, which was sold at the beginning of 2016, currency-adjusted net sales rose by 5.3%. Since operating income also improved by 6% to 2.3 billion euros, the return on net sales came to 15.3%.

With net sales of over 3.5 billion euros, the respiratory medication Spiriva (tiotropium) remains the best-selling medicine. The company’s diabetes business has established itself as a long-term growth driver, with net sales for the entire diabetes portfolio increasing significantly by around 49% in currency-adjusted terms to 1.1 billion euros (+63.8% in euro terms). The anticoagulant Pradaxa (dabigatran) contributed around 1.3 billion euros to net sales. Boehringer Ingelheim generated around 10% of its total net sales from consumer health care medicines in 2015.